Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development

Area of Science:

• Immunology
• Oncology
• Cell Death Research

Background:

• Immunogenic cell death (ICD) is a form of apoptosis induced by certain therapies, characterized by the release of pro-inflammatory signals.
• ICD promotes the recognition and clearance of dying tumor cells by phagocytes, suggesting a role in anticancer therapy efficacy.
• Demonstrating ICD's contribution in cancer patients remains challenging, and it may not be sufficient alone to overcome the tumor microenvironment's immunosuppression.

Purpose of the Study:

• To discuss the effects of danger signals from ICD on dendritic cell (DC) maturation and activation.
• To highlight the potential of ICD in improving cancer cell immunogenicity for DC-based vaccines.
• To explore the added value of ICD in adoptive immunotherapy protocols.

Main Methods:

• Review of existing literature on immunogenic cell death (ICD) and its effects on immune cells.
• Analysis of in vitro and animal models demonstrating ICD's role in anticancer therapy.
• Discussion of clinical evidence and potential applications of ICD in cancer treatment.

Main Results:

• ICD involves the release of danger signals that influence dendritic cell (DC) maturation and activation.
• ICD can enhance the immunogenicity of tumor cells, making them suitable as antigen sources for DC vaccines.
• ICD shows promise for improving the efficacy of adoptive immunotherapy strategies.

Conclusions:

• ICD plays a role in immune recognition and elimination of tumor cells.
• The exploitation of ICD holds potential for developing more effective cancer vaccines and immunotherapies.
• Further research is needed to fully elucidate and clinically apply ICD-based strategies in cancer treatment.